Jun 26, 2018 - an inflammatory cytokine that possesses extensive immunological functions. It has been ...... European journal of immunology 44, 2064â2073, ...
www.nature.com/scientificreports
OPEN
Received: 23 October 2017 Accepted: 26 June 2018 Published: xx xx xxxx
Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versushost disease after allogeneic haematopoietic stem cell transplantation Shuangzhu Liu1,3, Jingjing Han1,3, Huanle Gong2, Yongsheng Li4, Xiebing Bao1, Jiaqian Qi1, Hong Liu1,3, Jia Chen1,3, Xiaojin Wu1,3, Yang Xu1,2,3, Shoubao Ma1,2,3 & Depei Wu1,2,3 Acute graft-versus-host disease (aGVHD) is a major life-threatening complication after allogeneic haematopoietic stem cell transplantation. Interleukin-27 receptor alpha (IL-27Rα) is a co-receptor of IL-27, an inflammatory cytokine that possesses extensive immunological functions. It has been reported that IL-27Rα can exist in its soluble form (sIL-27Rα) in human serum and can function as a natural IL-27 antagonist. In this study, we examined serum sIL-27Rα levels and evaluated their prognostic value in aGVHD. A total of 152 subjects were prospectively recruited and separated into the training group (n = 72) and the validation group (n = 80). Serum sIL-27Rα at neutrophil engraftment was measured by ELISA. In the training set, a cut-off value of sIL-27Rα = 59.40 ng/ml was identified to predict grade II–IV aGVHD (AUC = 0.735, 95% CI 0.618–0.853, P = 0.001). Cumulative incidences of grade II–IV aGVHD (P = 0.004), relapse rate (P = 0.008), and non-relapse mortality (P = 0.008) in patients with low serum sIL-27Rα (≥59.40 ng/ml) were significantly higher than those of patients with high serum sIL-27Rα (
